Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2015 1
2016 1
2020 5
2021 2
2022 4
2023 2
2024 2
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
Real-World Safety and Outcome of First-Line Pembrolizumab Monotherapy for Metastatic NSCLC with PDL-1 Expression ≥ 50%: A National Italian Multicentric Cohort ("PEMBROREAL" Study).
Cafaro A, Foca F, Nanni O, Chiumente M, Coppola M, Russi A, Svegliati E, Baldo P, Orzetti S, Enrico F, Foglio F, Pinnavaia D, Ladisa V, Lauria Pantano C, Lerose R, Nardulli P, Ferraiuolo S, Maiolino P, De Stasio I, Gradellini F, Gasbarro AR, Santeramo R, Carrucciu G, Provasi R, Cirino M, Cappelletto PC, Fonzi E, Pasqualini A, Vecchia S, Veraldi M, De Francesco AE, Crinò L, Delmonte A, Masini C. Cafaro A, et al. Among authors: de francesco ae. Cancers (Basel). 2024 May 8;16(10):1802. doi: 10.3390/cancers16101802. Cancers (Basel). 2024. PMID: 38791882 Free PMC article.
A real-world retrospective, observational study of first-line pembrolizumab plus chemotherapy for metastatic non-squamous non-small cell lung cancer with PD-L1 tumor proportion score < 50% (PEMBROREAL).
Cafaro A, Foca F, Nanni O, Chiumente M, Coppola M, Baldo P, Orzetti S, Enrico F, Ladisa V, Lerose R, Nardulli P, Maiolino P, Gradellini F, Gasbarro AR, Carrucciu G, Provasi R, Cappelletto PC, Pasqualini A, Vecchia S, Veraldi M, De Francesco AE, Crinò L, Delmonte A, Masini C. Cafaro A, et al. Among authors: de francesco ae. Front Oncol. 2024 Mar 27;14:1351995. doi: 10.3389/fonc.2024.1351995. eCollection 2024. Front Oncol. 2024. PMID: 38601759 Free PMC article.
Pharmacovigilance in Italy: An overview.
Mazzitello C, Esposito S, De Francesco AE, Capuano A, Russo E, De Sarro G. Mazzitello C, et al. Among authors: de francesco ae. J Pharmacol Pharmacother. 2013 Dec;4(Suppl 1):S20-8. doi: 10.4103/0976-500X.120942. J Pharmacol Pharmacother. 2013. PMID: 24347976 Free PMC article. Review.
Pattern of triptans use: a retrospective prescription study in Calabria, Italy.
Scuteri D, Adornetto A, Rombolà L, Naturale MD, De Francesco AE, Esposito S, Zito M, Morrone LA, Bagetta G, Tonin P, Corasaniti MT. Scuteri D, et al. Among authors: de francesco ae. Neural Regen Res. 2020 Jul;15(7):1340-1343. doi: 10.4103/1673-5374.272630. Neural Regen Res. 2020. PMID: 31960822 Free PMC article.
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study.
Tassone P, Di Martino MT, Arbitrio M, Fiorillo L, Staropoli N, Ciliberto D, Cordua A, Scionti F, Bertucci B, Salvino A, Lopreiato M, Thunarf F, Cuomo O, Zito MC, De Fina MR, Brescia A, Gualtieri S, Riillo C, Manti F, Caracciolo D, Barbieri V, Di Paola ED, Di Francesco AE, Tagliaferri P. Tassone P, et al. Among authors: di francesco ae. J Hematol Oncol. 2023 Jun 26;16(1):68. doi: 10.1186/s13045-023-01468-8. J Hematol Oncol. 2023. PMID: 37365583 Free PMC article. Clinical Trial.
Biologics for Inflammatory Bowel Disease in Clinical Practice: A Calabria (Southern Italy) Prospective Pharmacovigilance Study.
Tallarico M, Palleria C, Ruffolo L, Spagnuolo R, Naturale MD, De Francesco AE, De Sarro C, Romeo R, Citraro R, Doldo P, Abenavoli L, Gallelli L, Luzza F, Leo A, De Sarro G. Tallarico M, et al. Among authors: de francesco ae. Pharmaceutics. 2022 Nov 13;14(11):2449. doi: 10.3390/pharmaceutics14112449. Pharmaceutics. 2022. PMID: 36432640 Free PMC article.
Real-World Safety Profile of Biologics Used in Rheumatology: A Six-Year Observational Pharmacovigilance Study in the Calabria Region.
Gagliardi A, Iaquinta FS, Grembiale RD, De Sarro C, Fabiano A, Fraija D, Palleria C, Romeo R, De Francesco AE, Naturale MD, Citraro R, Gallelli L, Leo A, De Sarro G. Gagliardi A, et al. Among authors: de francesco ae. Pharmaceutics. 2022 Oct 28;14(11):2328. doi: 10.3390/pharmaceutics14112328. Pharmaceutics. 2022. PMID: 36365146 Free PMC article.
Safety profile of biologic drugs for psoriasis in clinical practice: An Italian prospective pharmacovigilance study.
Iannone LF, Bennardo L, Palleria C, Roberti R, De Sarro C, Naturale MD, Dastoli S, Donato L, Manti A, Valenti G, D'Amico D, D'Attola S, De Francesco AE, Bosco V, Donato Di Paola E, Nisticò SP, Citraro R, Russo E, De Sarro G. Iannone LF, et al. Among authors: de francesco ae. PLoS One. 2020 Nov 3;15(11):e0241575. doi: 10.1371/journal.pone.0241575. eCollection 2020. PLoS One. 2020. PMID: 33141869 Free PMC article.
Obinutuzumab Plus Chemotherapy Compared with Rituximab Plus Chemotherapy in Previously Untreated Italian Patients with Advanced Follicular Lymphoma at Intermediate-High Risk: A Cost-Effectiveness Analysis.
Bellone M, Pradelli L, Molica S, De Francesco AE, Ghislieri D, Guardalben E, Caputo A. Bellone M, et al. Among authors: de francesco ae. Clinicoecon Outcomes Res. 2021 Jul 22;13:661-671. doi: 10.2147/CEOR.S317885. eCollection 2021. Clinicoecon Outcomes Res. 2021. PMID: 34321898 Free PMC article.
17 results